Samsung's Galaxy Buds have FDA hearing-aid clearance, with limits

Samsung's earbuds have been quietly creeping toward medical status for six years. On 11 August the creep ended: the company announced that the US Food and Drug Administration had cleared a Hearing Aid feature built into the Galaxy Buds, letting the Buds 3 Pro and Buds 4 Pro work as over-the-counter hearing aids for adults with perceived mild to moderate hearing loss — no prescription, no clinic appointment.

That is a genuinely useful thing, and it is also narrower than the headlines suggest. Worth separating the two.

Two pieces of software, not new hardware. The first is a Hearing Test that lives in the Galaxy Buds menu inside Settings rather than in a separate app. The Hearing Review reports it runs roughly five minutes, uses clinical-grade pure-tone audiometry, tests each ear individually and produces an audiogram, sorting your hearing into normal or one of four bands — mild, moderate, severe or profound. That test is registered as software as a medical device.

The second piece is the amplification itself, and only for people whose results land in the mild-to-moderate range. Samsung says it boosts the sounds people typically lose first: high frequencies, whispers nearby, voices across a room. Noise elimination and beamforming narrow the pickup to what is in front of you — features PCMag notes are usually reserved for premium prescription devices. SoundGuys adds detail on the controls users get: run both buds or just one, set the volume, choose front-only or all-round pickup, and dial the background-noise reduction up or down rather than accepting whatever the algorithm decides.

Both models use NAL-NL2 to calculate the fitting targets. The Hearing Review is fair about what that means, describing the formula as one that, "while now not the newest, has long been used as the clinical standard formula for fitting prescription hearing aids." So: a real, established prescription method, not a bespoke consumer EQ curve with medical branding stapled on.

Samsung did not arrive here in one jump. It shipped a Personal Sound Amplification Product feature on the Galaxy Buds+ back in 2020, and that feature was clinically validated the following year. For the OTC hearing aid, the company worked with the National Acoustic Laboratories and Samsung Medical Center, and ran validation studies at Vanderbilt University Medical Center, San Jose State University and the University of Memphis.

Hon Pak, senior vice president and head of the digital health team for Samsung's Mobile eXperience business, framed the clearance in access terms: "Hearing health is a vital component of our overall well-being, profoundly impacting how we communicate, connect with loved ones and engage with the world. With the latest clearance from the FDA, we are expanding access to hearing support and making proactive care effortless by integrating the Hearing Test and Hearing Aid functionality directly into the Galaxy Buds."

The access argument has numbers behind it. The World Health Organization puts more than 1.5 billion people worldwide as living with some degree of hearing loss, projected to reach 2.5 billion by 2050, with cost, stigma and distance from professional care all keeping people away from treatment. A $249 pair of earbuds most people would not be embarrassed to wear on a bus solves at least two of those three.

Nothing ships today. Samsung has targeted the fourth quarter of 2026 for the rollout in the US and select approved markets. There is no announced date inside that window. Full support also requires a compatible Galaxy device running One UI 8 or later.

Geography matters more than usual here. The Korea Herald points out that the FDA clearance applies only to the US market, and that Samsung has not announced a rollout plan for South Korea — the company's home market, and one where the buds already sell in volume. If you are outside the US, "select other approved markets" is doing considerable work in that sentence, and Samsung has not published the list.

There is also the disclaimer Samsung attaches to its own feature, which PCMag quotes directly: it "is not a substitute for professional diagnosis or treatment by a qualified clinician." Read that against the four-band test output. Buds that tell you your hearing loss is severe or profound will not then amplify for you, because the OTC clearance does not extend that far. In that scenario the test has done its job by sending you to an audiologist, which is a useful outcome, just not the one the marketing leads with.

Not yet, and not on the strength of a promise. Apple got FDA clearance for the equivalent AirPods Pro 2 feature in 2024, so Samsung is two years behind rather than breaking ground, and the practical question for anyone shopping now is whether the buds are good enough on their own merits at $249. If you already own Buds3 Pro or Buds4 Pro and a compatible Galaxy phone, the Q4 software rollout could add substantial value, but availability still depends on regulatory approval in your market. If you are buying specifically for the hearing feature and you do not live in the US, wait for Samsung to name your market before you spend anything.